FDA Deals Setback To CytoDyn’s HIV Drug; Gilead Reprimanded By British Firms For HIV Drug Claims
The Food and Drug Administration's refusal to accept CytoDyn's drug application could cause a lengthy setback for the drug. Meanwhile, Britain's pharmaceutical trade group spoke out against Gilead for disseminating information that unfairly compared one of its HIV drugs with a rival medicine sold by ViiV Healthcare, which is working toward an injectable medicine that prevents AIDS.